Nissle 1917 (EcN), the active component of Mutaflor, is a notable probiotic from Gram-negative to treat Crohn's disease and irritable bowel syndrome. Therefore, a comprehensive genomic database maximizes the systemic probiotic assessment to discover EcN's role in human health. Recently, advanced synthetic and genetic tools have opened up a rich area to execute EcN as "living medicines" with controllable functions. Incorporating unique biomarkers allows the engineered EcN to switch genes on and off in response to environmental cues. Since EcN holds promise as a safe nature vehicle, more studies are desired to fully realize a wide range of probiotic potential for disease treatment. This review aims to deliver a historical origin of EcN, discuss the recent promising genetic toolbox in the rational design of probiotics, and pinpoint the clinical translation and evaluation of engineered EcN and . The summary of safety concerns, strategies of biotherapeutics development, and the challenges and prospects of engineered EcN is also concluded.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/1040841X.2022.2109405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineering probiotic Escherichia coli for inflammation-responsive indoleacetic acid production using RiboJ-enhanced genetic circuits.
J Biol Eng
January 2025
Synthetic Biology Research Center and the K-Biofoundry, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea.
Background: As our understanding of gut microbiota's metabolic impacts on health grows, the interest in engineered probiotics has intensified. This study aimed to engineer the probiotic Escherichia coli Nissle 1917 (EcN) to produce indoleacetic acid (IAA) in response to gut inflammatory biomarkers thiosulfate and nitrate.
Results: Genetic circuits were developed to initiate IAA synthesis upon detecting inflammatory signals, optimizing a heterologous IAA biosynthetic pathway, and incorporating a RiboJ insulator to enhance IAA production.
Anti-tumor activity of an αPD-L1-PE38 immunotoxin delivered by engineered Nissle 1917.
Int J Biol Macromol
January 2025
College of Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China. Electronic address:
Although immune checkpoint inhibitors specifically targeting the PD-1/PD-L1 axis have exhibited remarkable clinical success, they are not uniformly effective across all patient cohorts. Immunotoxins, a novel class of cancer therapeutics, offering a promising alternative. PD-L1, which is also present in certain normal tissues, limits its suitability as an ideal target for immunotoxins.
View Article and Find Full Text PDFGenetically Encoded Biosensors for Constrained Biological Functions in Probiotic Nissle.
ACS Synth Biol
January 2025
State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Fujian 361102, China.
The probiotic Nissle (EcN) is an exceptional strain that has attracted significant attention not only for its clinical efficacy in the treatment and prevention of gastrointestinal disorders but also as a burgeoning microbial chassis for living therapeutic applications. However, there is an immediate necessity to develop conditional expression systems that confine the activity of EcN specifically in the gastrointestinal tract, to avoid influencing the environment. Here, we constructed two genetically encoded interchangeable sensors responsive to body temperature at 37 °C, and small molecules such as protocatechuic acid (PCA), a metabolite found in green tea.
View Article and Find Full Text PDFNeuroimaging signatures and a deep learning modeling for early diagnosing and predicting non-pharmacological therapy success for subclinical depression comorbid sleep disorders in college students.
Int J Clin Health Psychol
December 2024
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510405, China.
Objective: College students with subclinical depression often experience sleep disturbances and are at high risk of developing major depressive disorder without early intervention. Clinical guidelines recommend non-pharmacotherapy as the primary option for subclinical depression with comorbid sleep disorders (sDSDs). However, the neuroimaging mechanisms and therapeutic responses associated with these treatments are poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!